Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study
about
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation TherapyPopulation Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature.Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation.Medicating patients during extracorporeal membrane oxygenation: the evidence is building.Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration.Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.Vancomycin Dosing in Pediatric Extracorporeal Membrane Oxygenation: Potential Impacts of New Technologies.Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit.Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure.Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.Idiopathic pulmonary fibrosis patient supported with extracorporeal membrane oxygenation for 403 days while waiting for a lung transplant: A case report.Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations
P2860
Q31032098-F97EECB5-0025-46D4-B5A1-12107960A781Q37283031-982EB6CB-026D-4726-BBBB-609CBB3E1C0DQ38374584-53A2A772-DC04-4E8B-9D50-B3BA4A40D628Q38935160-38EA7C6B-ECD2-4CC5-847F-0E4A9C561A26Q39033001-EA5A294F-1F1E-4DF5-A54F-C5AEA7DE4C9FQ39188586-2B196472-C500-4851-80F8-E4B122885750Q40076368-C6546438-B4CC-4FFD-B58F-A7AB95F0AE7FQ40321062-750BC7B9-6B00-4D9E-BCF9-FD5426DBF0BCQ42376928-E7052A95-B19B-4860-82B8-8EA2003EB779Q45069269-FB236191-94E7-493E-8F82-C9AE2822FCE1Q47632337-6944AE93-3184-433A-AC3A-FD9BB6931858Q52589876-C3397965-0E84-44D2-81F2-41B7CFEC7C31Q55393633-617318AC-A33F-44A0-B397-616B033D8964Q55491824-4AA138D7-A68F-45B9-9B40-B8A39588B6EBQ58699337-2A7C9C8B-6E9F-460F-B1D5-8811E04235A4
P2860
Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Vancomycin population pharmaco ...... herapy: a matched cohort study
@ast
Vancomycin population pharmaco ...... herapy: a matched cohort study
@en
Vancomycin population pharmaco ...... herapy: a matched cohort study
@nl
type
label
Vancomycin population pharmaco ...... herapy: a matched cohort study
@ast
Vancomycin population pharmaco ...... herapy: a matched cohort study
@en
Vancomycin population pharmaco ...... herapy: a matched cohort study
@nl
prefLabel
Vancomycin population pharmaco ...... herapy: a matched cohort study
@ast
Vancomycin population pharmaco ...... herapy: a matched cohort study
@en
Vancomycin population pharmaco ...... herapy: a matched cohort study
@nl
P2093
P2860
P50
P1433
P1476
Vancomycin population pharmaco ...... herapy: a matched cohort study
@en
P2093
Asmae Belhaj
Daniel de Backer
Fabio Silvio Taccone
Frédérique Jacobs
Marjorie Beumier
Stefano Cristallini
P2860
P2888
P356
10.1186/S13054-014-0632-8
P577
2014-11-22T00:00:00Z
P5875
P6179
1012953824